青岛海尔生物医疗股份有限公司 募集资金管理制度 1 公司发现控股股东、实际控制人及其他关联人占用募集资金的，应当及时要 求归还，并披露占用发生的原因、对公司的影响、清偿整改方案及整改进展情况。 第八条 募投项目通过公司的子公司或公司控制的其他企业实施的，公司应 当确保该子公司或控制的其他企业遵守其募集资金管理制度。 第一章 总 则 第一条 为规范青岛海尔生物医疗股份有限公司（以下简称"公司"）募集 资金的使用与管理，提高募集资金的使用效率，防范资金使用风险，确保资金使 用安全，保护投资者的利益，根据《中华人民共和国公司法》《中华人民共和国 证券法》《上海证券交易所科创板上市公司自律监管指引第1号——规范运作》 《上市公司募集资金监管规则》《上市公司监管指引第2号——上市公司募集资 金管理和使用的监管要求》等法律法规、规范性文件，以及《青岛海尔生物医疗 股份有限公司章程》（以下简称《公司章程》）的要求，结合公司实际情况，制 订本制度。 第二条 本制度适用于公司通过发行股票或者其他具有股权性质的证券，向 投资者募集并用于特定用途的资金监管，但不包括公司为实施股权激励计划募集 的资金监管。 第三条 公司募集资金应当 ...

信息披露事务管理制度 第一章 总 则 第一条 为规范青岛海尔生物医疗股份有限公司（以下简称"公司"）的信息披露行 为，正确履行信息披露义务，切实保护公司、股东、债权人及其他利益相关者的合法权 益，根据《中华人民共和国公司法》、《中华人民共和国证券法》（以下简称"《证券 法》"）、《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）、 《上市公司信息披露管理办法》和《科创板上市公司自律监管指南第3号——日常信息披 露》等有关规定，结合《青岛海尔生物医疗股份有限公司章程》（以下简称"《公司章 程》"），制订本制度。 第二条 本制度适用于以下人员和机构： （一）公司董事和董事会； （二）公司董事会秘书和证券部； （三）公司高级管理人员； （四）公司各部门以及各子公司、分公司的负责人； 青岛海尔生物医疗股份有限公司 （五）公司控股股东和持有公司5%以上股份的股东； （六）其他依法负有信息披露职责的人员和机构。 第三条 本制度由公司董事会制订。董事会应当负责并保证本制度的有效实施，确保 公司相关信息披露的及时性和公平性，以及信息披露内容的真实、准确、完整。 公司证券部是董事会领导下负责公司信息披露事务的常设 ...

海尔生物公告，第三季度营收为5.66亿元，同比增长1.24%；净利润为5565.17万元，同比下降25.60%。 前三季度营收为17.61亿元，同比下降1.17%；净利润为1.98亿元，同比下降35.83%。 ...

Investment Rating - The investment rating for the company is "Accumulate" (first coverage) [1][7] Core Viewpoints - The company is a pioneer in the field of ultra-low temperature storage for biological cells in China, backed by Changhong Group and supported by the Chinese Academy of Sciences. It has developed several industry-leading products, including ultra-low temperature storage boxes reaching -180°C, and has a strong patent portfolio with 436 patents as of the end of 2024 [4][7][21]. - The company has shown stable revenue growth, with a projected revenue of 320.91 million yuan in 2025, reflecting an 8.50% increase year-on-year. The net profit is expected to reach 25.22 million yuan, a 39.43% increase [5][7]. - The domestic medical device market is projected to grow significantly, with the market size expected to exceed 1.8 trillion yuan by 2030, and the biological low-temperature storage equipment market is anticipated to grow from 6.772 billion yuan in 2022 to 21.543 billion yuan by 2028 [7][9]. Company Overview - The company, established in 2002, has developed a diverse product portfolio in the ultra-low temperature storage sector, including products that operate in the temperature range of -196°C to 8°C, widely used in medical, research, and biopharmaceutical fields [13][28]. - The company has received numerous accolades, including being recognized as a national-level "specialized and innovative" small giant enterprise and has won various awards for technological innovation [17][21]. Financial Forecast - The financial forecast indicates total revenue of 302.79 million yuan in 2023, with a decline of 25.51%, followed by a slight recovery in 2024 to 295.77 million yuan. The company is expected to achieve a revenue of 320.91 million yuan in 2025, with a growth rate of 8.50% [5][7]. - The projected net profit for 2025 is 25.22 million yuan, representing a significant increase of 39.43% compared to 2024 [5][7]. Industry Analysis - The medical device industry is experiencing rapid growth, driven by various factors, including policy support and increasing demand for domestic medical equipment. The company is well-positioned to benefit from these trends as a leading player in the biological low-temperature storage market [9][28]. - The company has a competitive edge in the market, having ranked among the top three domestic brands in low-temperature storage equipment, and is expected to capture more market share due to its technological advantages [29][40].

Investment Rating - The investment rating for the company is "Accumulate" (首次) [1][9] Core Insights - The company is a pioneer in the field of ultra-low temperature storage for biological cells, breaking foreign monopolies and focusing on technological innovation and market expansion [6][30] - The company has achieved a revenue of 1.5 billion yuan in the first half of 2025, with a year-on-year growth of 2.16%, and a net profit of 11.05 million yuan, reflecting a 5.94% increase [9][31] - The domestic medical device market is projected to reach 1.35 trillion yuan in 2024, with a compound annual growth rate of 7.53% from 2025 to 2030 [9][31] Company Overview - The company, established in 2002, is backed by Changhong Group and supported by the Chinese Academy of Sciences, focusing on ultra-low temperature storage [9][15] - It has received numerous accolades, including being recognized as a national-level "Little Giant" enterprise and winning the National Technology Invention Award [19][23] - The company has a diverse product portfolio, including ultra-low temperature storage boxes and laboratory equipment, with applications in medical, research, and biopharmaceutical fields [30][31] Financial Performance - Revenue projections for 2025-2027 are 320.91 million, 356.79 million, and 406.46 million yuan, with respective growth rates of 8.50%, 11.18%, and 13.92% [7][9] - The net profit for the same period is expected to be 25.22 million, 29.55 million, and 32.70 million yuan, with growth rates of 39.43%, 17.19%, and 10.64% [7][9] - The company's gross margin is reported at 36.67%, with a net margin of 7.35% for the first half of 2025 [9][31] Industry Analysis - The medical device industry is driven by policy and demand, with a significant push for domestic alternatives [11][30] - The market for biological low-temperature storage equipment is expected to grow from 6.772 billion yuan in 2022 to 21.543 billion yuan by 2028 [9][31] - The company is positioned to benefit from increasing demand for medical equipment in rural areas and supportive government policies [9][31] Product and Technology - The company has developed a comprehensive range of products, including ultra-low temperature storage devices and laboratory equipment, covering temperature ranges from -196°C to 8°C [30][31] - It has a strong focus on R&D, with 11.19% of revenue allocated to research, resulting in 436 patents as of the end of 2024 [9][45] - The company aims to enhance its technological capabilities and expand its product offerings in the ultra-low temperature storage sector [42][45]

Summary of Hailong Cold Chain Conference Call Company Overview - **Company**: Hailong Cold Chain - **Industry**: Cold Chain Equipment Manufacturing Key Points and Arguments Financial Performance - **Q3 2025 Revenue**: - Frozen domestic sales revenue reached 281 million CNY, a year-on-year increase of 25.79% driven by strong ice cream sales and increased equipment deployment [2][4] - Cold storage business grew over 20% in the first three quarters, attributed to new customer acquisition and increased supply share, particularly with major clients like Coca-Cola and Pepsi [2][12] - Supermarket domestic sales revenue surged 140% to 130 million CNY, mainly due to increased orders from traditional clients and new partnerships in the snack wholesale sector [2][19] Market Challenges and Opportunities - **North American Market**: - Faced challenges due to tariffs and prior customer stockpiling, leading to poor performance this year. However, recovery is expected next year as the Indonesian factory can provide lower tariff supply channels (19%) [2][8] Gross Margin Analysis - **Gross Margin Decline**: - Overall gross margin decreased due to changes in product mix, particularly in frozen products where margins fell by approximately 2 percentage points [2][13] - Cold storage domestic gross margin improved to 14.5%, while external gross margin decreased to 22.8%, down 4 percentage points year-on-year due to customer stockpiling and tariff pressures [15] Future Outlook - **Optimistic Projections**: - The company maintains a positive outlook for all business segments, expecting a recovery in North American orders and continued growth in domestic markets, particularly in ice cream sales [9][11] - The Indonesian factory is on track for trial production by the end of November, with a first-year target capacity of 100,000 units and a long-term goal of 500,000 units [2][17] Sales and Marketing Strategy - **Sales Expense Management**: - Sales expenses have remained stable, with a slight increase of about 1 million CNY compared to last year, indicating effective cost management despite growth initiatives [18] Product Development and Market Expansion - **Smart Cabinet Market**: - Demand for smart cabinets is expected to grow, although competition for prime locations has intensified, leading to short-term fluctuations in deployment [21] - **Pharmaceutical Cabinet Development**: - The pharmaceutical cabinet business is in early stages, with product trials ongoing but expected to take time before generating significant revenue [24][25] Dividend Policy - **Dividend Commitment**: - The company plans to maintain a dividend policy of no less than 50% [3][28] Conclusion - **Growth Strategy**: - The company is focused on expanding its market presence, particularly in Southeast Asia, and enhancing its product offerings to maintain competitive advantages in both domestic and international markets [16][22]

Core Viewpoint - The article discusses the importance and development factors of platelet constant temperature oscillating storage boxes, highlighting their role in ensuring the safety and effectiveness of clinical blood transfusions through advanced temperature control and oscillation technology [2][4]. Group 1: Definition and Importance - Platelet constant temperature oscillating storage boxes are medical devices that maintain a stable temperature environment to preserve platelet activity, ensuring safe and effective blood transfusions [2]. - These devices prevent platelet aggregation and sedimentation, maintaining uniform distribution and functional integrity, and are equipped with temperature sensors and alarm systems for real-time monitoring [2]. Group 2: Development Factors - The growth of platelet constant temperature oscillating storage boxes is driven by factors such as aging population, improved medical standards, increased surgical procedures, regulatory requirements, public health emergencies, and technological integration [4]. - The aging population, particularly in emerging economies like China, is leading to a rigid increase in clinical blood demand, especially for platelet transfusions during surgeries [5]. Group 3: Quality and Safety Requirements - Advances in medical technology have raised the performance requirements for storage boxes, necessitating precise temperature control and oscillation parameters to accommodate new storage solutions [7][8]. - The emphasis on green healthcare has led to the adoption of low-power motors and environmentally friendly refrigerants, enhancing sustainability and user-friendliness [8]. Group 4: Regulatory and Public Health Considerations - Stricter regulations on blood product management are pushing the development of high-precision and reliable storage boxes, requiring compliance with quality management standards [9]. - The COVID-19 pandemic highlighted vulnerabilities in the blood supply chain, prompting the need for larger, intelligent storage solutions to ensure adequate platelet reserves during emergencies [10]. Group 5: Future Trends - The future of platelet constant temperature oscillating storage boxes is expected to focus on smart and digital transformation, with over 70% of market products projected to integrate AI-driven predictive maintenance and real-time data analysis by 2027 [11]. - There is a strategic shift towards integrated solutions that encompass the entire blood management process, with expectations that this model will account for over 60% of market share by 2028 [12]. - The market for portable storage boxes is anticipated to grow significantly, driven by the increasing demand for emergency medical services and mobile blood banks [13]. Group 6: Industry Leaders - Qingdao Haier Biomedical is a leader in the field, providing innovative digital solutions for blood safety management, with a reported annual revenue of 2.284 billion yuan in 2024 [15]. - Haier's platelet constant temperature oscillating storage boxes are designed to meet stringent storage requirements, integrating IoT technology for enhanced monitoring and data traceability [15][16].

Core Points - The company will hold an investor briefing on October 31, 2025, to discuss its Q3 2025 financial results and operational performance [2][3][4] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [2][5] - Investors can submit questions from October 24 to October 30, 2025, and the company will address common concerns during the briefing [2][4][6] Meeting Details - The investor briefing is scheduled for October 31, 2025, from 11:00 AM to 12:00 PM [2][5] - The location for the meeting is the Shanghai Stock Exchange Roadshow Center, accessible via the website [2][5] - Participants can join the meeting online and will have the opportunity to ask questions [4][5] Contact Information - For inquiries, investors can contact the Haier Biomedical Securities Department at phone number 0532-88935566 or via email at haierbiomedical@haierbiomedical.com [6]

证券代码：688139 证券简称：海尔生物 公告编号：2025-048 青岛海尔生物医疗股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 重要内容提示： 会议召开时间：2025 年 10 月 31 日(星期五)上午 11:00-12:00 会议召开地点：上海证券交易所上证路演中心（网址： 二、 说明会召开的时间、地点 （一） 会议召开时间：2025 年 10 月 31 日 （星期五） 11:00-12:00 （二） 会议召开地点：上证路演中心 （三） 会议召开方式：上证路演中心网络互动 https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 10 月 24 日（星期五）至 10 月 30 日（星期四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 haierbiomedical@haierbiomedical.com 进行提问。公司将在说明会上对投资者 普遍关注的问题 ...

Core Viewpoint - Haier Biomedical's major shareholder, Qingdao Guoxin Financial Holdings Co., Ltd., has increased its stake, reflecting confidence in the future of the life sciences industry and recognition of Haier Biomedical's governance, industry position, business capabilities, operational results, and risk management [1] Group 1: Shareholder Information - The controlling shareholder of the increased stake is Qingdao Guoxin Financial Holdings Co., Ltd., with actual control by the State-owned Assets Supervision and Administration Commission of the Qingdao Municipal People's Government [1] - The investment is based on the shareholder's long-term positive outlook on the life sciences sector and the company's performance [1] Group 2: Future Plans and Strategies - Haier Biomedical aims to deepen its focus on four major industries and enhance the integration of AI technology with life sciences and medical innovation scenarios [1] - The company plans to accelerate its globalization process to provide returns to investors [1]